Fantastic feedback for the 3rd Annual Biosimilars & Biobetters Congress

Taking place on the 20th & 21st April 2015 in London, Oxford Global's 3rd Annual Biosimilars & Biobetters Congress brought together over 300 professionals working within Biosimilars, Biobetters and Biotherapeutics. Co-located with the 8th Annual Proteins & Antibodies Congress and 2nd Annual Peptides Congress, the two days allowed all of our delegates and sponsors to attend over 40 presentations, panel discussions and case studies focusing on the key issues of market access strategies, opportunities and commercial challenges, and developing biosimilars and biobetters. Delegates were also provided with the opportunity to network with industry leaders and solution providers in both formal and informal sessions.

Presentations included:

Facilitating Acceptance Of Biosimilars By Clinicians: Education Above All: Uwe Gudat, Head of Safety, Biosimilars, Merck Serono

Challenges And Opportunities In Developing Best In Class Biosuperiors Or Biobetter Biologics: Rakesh Dixit, Vice President R&D, MedImmune

Evolution Of Biosimilar Regulatory Pathways In Emerging Markets: Julie O'Brien, Senior Manager, Emerging Markets Regulatory Policy, Pfizer

Biosimilars 2015: Nine Years After The 1st "Generic Biological" Was Approved By The FDA, Where Do We Stand? Alexandre Richard, Head of Business Intelligence - Strategy & Business Development, Sanofi

We would like to thank all delegates and sponsors for providing us with testimonials from across the 2 days.

Delegate Testimonials for 2015 included:

"There was a nice combination of presentations, parallel sessions to choose from and opportunities to interact with service providers." Associate Director, SHIRE

"The presentations really were excellent. They demonstrated very well the depth and rigour of research that can go on in the pharma industry today. The organisation was really good and you have excellent staff. I loved the workshop too!" Associate Director, Pfizer

"I enjoyed the presence of the bigger pharma speakers, and the 1-2-1 meetings were excellent." Senior Scientist, AIMM Therapeutics

Sponsor Testimonials for 2015 included:

"The organisation was well above average. The duration of the congress and the exhibition areas were excellent, as was the quality of the speakers." CEO, CHELATEC

"Good footfall to the booth and good leads for our Wokingham site. Thanks for your professional administration of the event- see you next time!" Sales Manager, SGS

"Really well organised, especially the 1-2-1 meetings. I was impressed with the other attendees and the talks were very relevant." BioPharma Market Specialist, Agilent Technologies

Following the event, we analyse statistics and feedback from attendees, and we are proud to announce that we achieved an "Above Average" or "Excellent" rating in all categories including:

- Relevance and Quality of the Delegates and Solution Providers

- Organisation of the One-to-one Meetings

- Format and Content of the Congress Agenda

This is great news for everyone involved in the production of the 3rd Annual Biosimilars & Biobetters Congress.

Oxford Global will shortly start production on the 4th Annual Biosimilars & Biobetter Congress, again co-located with the 9th Annual Proteins & Antibodies Congress and the 3rd Annual Peptides Congress. For further information on attending or sponsoring the event, please contact Steph Punfield on +44 (0)1865 248455 or by email on s.punfield@oxfordglobal.co.uk.